BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33905671)

  • 1. NPRL2 reduces the niraparib sensitivity of castration-resistant prostate cancer via interacting with UBE2M and enhancing neddylation.
    Zhao X; Jiang L; Hu D; Tang Y; Zhao G; Du X; Luo S; Tang W
    Exp Cell Res; 2021 Jun; 403(2):112614. PubMed ID: 33905671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
    Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
    Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NPRL2 enhances autophagy and the resistance to Everolimus in castration-resistant prostate cancer.
    Chen Z; Jiang Q; Zhu P; Chen Y; Xie X; Du Z; Jiang L; Tang W
    Prostate; 2019 Jan; 79(1):44-53. PubMed ID: 30178500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting NPRL2 to enhance the efficacy of Olaparib in castration-resistant prostate cancer.
    Chen X; Chen Z; Zheng B; Tang W
    Biochem Biophys Res Commun; 2019 Jan; 508(2):620-625. PubMed ID: 30522863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXO1 inhibits prostate cancer cell proliferation via suppressing E2F1 activated NPRL2 expression.
    Tang Y; Jiang L; Zhao X; Hu D; Zhao G; Luo S; Du X; Tang W
    Cell Biol Int; 2021 Dec; 45(12):2510-2520. PubMed ID: 34459063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of Nedd8‑conjugating enzyme UBE2M suppresses the proliferation and induces the apoptosis of intrahepatic cholangiocarcinoma cells.
    Zhao B; Gao C; Shi D; Mao J; Zhao J; Guo L; Guo J; Jiao Z
    Oncol Rep; 2019 Dec; 42(6):2670-2679. PubMed ID: 31545502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
    Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation.
    Li X; Pham V; Tippin M; Fu D; Rendon R; Song L; Uchio E; Hoang BH; Zi X
    Cell Commun Signal; 2019 Mar; 17(1):25. PubMed ID: 30885218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UBE2M Is a Stress-Inducible Dual E2 for Neddylation and Ubiquitylation that Promotes Targeted Degradation of UBE2F.
    Zhou W; Xu J; Tan M; Li H; Li H; Wei W; Sun Y
    Mol Cell; 2018 Jun; 70(6):1008-1024.e6. PubMed ID: 29932898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA PCAT1 activates AKT and NF-κB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKα complex.
    Shang Z; Yu J; Sun L; Tian J; Zhu S; Zhang B; Dong Q; Jiang N; Flores-Morales A; Chang C; Niu Y
    Nucleic Acids Res; 2019 May; 47(8):4211-4225. PubMed ID: 30773595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitrogen permease regulator-like 2 enhances sensitivity to oxaliplatin in colon cancer cells.
    Liu MN; Liu AY; Du YJ; Pei FH; Wang XH; Chen J; Liu D; Liu BR
    Mol Med Rep; 2015 Jul; 12(1):1189-96. PubMed ID: 25777765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer.
    Li L; Kang J; Zhang W; Cai L; Wang S; Liang Y; Jiang Y; Liu X; Zhang Y; Ruan H; Chen G; Wang M; Jia L
    EBioMedicine; 2019 Jul; 45():81-91. PubMed ID: 31208947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway.
    Zhou H; Lu J; Yang CY; Sun Y; Wang S
    Adv Exp Med Biol; 2020; 1217():349-362. PubMed ID: 31898237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting neddylation E2s: a novel therapeutic strategy in cancer.
    Zheng YC; Guo YJ; Wang B; Wang C; Mamun MAA; Gao Y; Liu HM
    J Hematol Oncol; 2021 Apr; 14(1):57. PubMed ID: 33827629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neddylation E2 UBE2F Promotes the Survival of Lung Cancer Cells by Activating CRL5 to Degrade NOXA via the K11 Linkage.
    Zhou W; Xu J; Li H; Xu M; Chen ZJ; Wei W; Pan Z; Sun Y
    Clin Cancer Res; 2017 Feb; 23(4):1104-1116. PubMed ID: 27591266
    [No Abstract]   [Full Text] [Related]  

  • 16. Overactivated neddylation pathway as a therapeutic target in lung cancer.
    Li L; Wang M; Yu G; Chen P; Li H; Wei D; Zhu J; Xie L; Jia H; Shi J; Li C; Yao W; Wang Y; Gao Q; Jeong LS; Lee HW; Yu J; Hu F; Mei J; Wang P; Chu Y; Qi H; Yang M; Dong Z; Sun Y; Hoffman RM; Jia L
    J Natl Cancer Inst; 2014 Jun; 106(6):dju083. PubMed ID: 24853380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-securinine inhibits cell growth and metastasis of human androgen-independent prostate cancer DU145 cells via regulating mitochondrial and AGTR1/MEK/ERK/STAT3/PAX2 apoptotic pathways.
    Zhang D; Liu H; Yang B; Hu J; Cheng Y
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30975734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.
    Liao Y; Liu Y; Xia X; Shao Z; Huang C; He J; Jiang L; Tang D; Liu J; Huang H
    Theranostics; 2020; 10(8):3366-3381. PubMed ID: 32206096
    [No Abstract]   [Full Text] [Related]  

  • 19. Overexpression of Nitrogen Permease Regulator Like-2 (NPRL2) Enhances Sensitivity to Irinotecan (CPT-11) in Colon Cancer Cells by Activating the DNA Damage Checkpoint Pathway.
    Liu S; Liu B
    Med Sci Monit; 2018 Mar; 24():1424-1433. PubMed ID: 29519997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.
    Lin HP; Lin CY; Huo C; Hsiao PH; Su LC; Jiang SS; Chan TM; Chang CH; Chen LT; Kung HJ; Wang HD; Chuu CP
    Oncotarget; 2015 Mar; 6(9):6684-707. PubMed ID: 25788262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.